Stock screener

PMN

Conviction 42HealthcareScan · Thu, Jun 25, 2026
PMN$10.52+2.73%
ResistanceSupportVol 14Insider buy
63 bars
Vol MA14 17.64K
Mar 26Apr 14May 1May 19Jun 8Jun 25
ProMIS Neurosciences Inc.PHARMACEUTICAL PREPARATIONSwww.promisneurosciences.com
Price10.52
Change+2.73%
Gap+2.44%
Rel volume2.33×
Avg volume20.68K
Avg $ vol211.14K
SMA 2010.24
SMA 5010.62
SMA 2008.79
Price vs 50-0.90%
Price vs 200+19.73%
MA stackmixed
50/200 cross
Supertrenddown · 11.81
RSI (14)51
MACD hist0.11
MACD cross
Stoch %K / %D72 / 70
ADX (14)18
+DI / −DI14 / 19
RSI divergence
MACD divergence
ATR %+6.22%
ADR %6.50%
52w high24.79
52w low0.2895
From 52w high-57.56%
Above 52w low+3533.85%
New 52w highNo
SqueezeOn · 42d
Bollinger width17.43%
%B0.66
Donchian pos62.86%
Donchian high11.37
Donchian low9.09
AVWAP (52w high)13.61
vs AVWAP high-22.70%
AVWAP (52w low)13.41
vs AVWAP low-21.55%
OBV trendFlat
Chaikin MF (20)-0.27
Today vs 20d2.33×
Avg vol (14d)17.64K
Avg vol (20d)20.68K
Avg $ vol (20d)211.14K
Market cap94.34M
RS 3m (vs SPY)-53.51%
RS 6m (vs SPY)+12.03%
RS line new highNo
Trend template3/8
Technical rank70.4
1 week+1.35%
1 month+1.54%
3 months-33.63%
6 months+29.40%
1 year+2069.07%
YTD+47.44%
P/E-2.38
P/B1.55
P/S
P/FCF-3.35
EPS-22.61
Div yield
ROE-65.42%
ROA-58.92%
Debt/Eq0.00
Current9.92
EV/EBITDA
Gross margin
Net margin
Rev growth
EPS growth-1529.33%
Price target
Target upside
Analyst rating
Institutional
Ent. value30.53M
Revenue
Net income-8.24M
Gross profit
Free cash flow-28.12M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out8.97M
Employees11
ListedFri, Sep 30, 2005
Free float7.88M
Float %87.9%
Short interest188.79K
Days to cover8.6d
Short volume8.3%
Squeeze score45 / 100
Next earnings
EPS forecast
Last EPS vs est
Last surprise
Setup gradeD
Conviction42 / 100
Pattern quality
Tech rank70.4 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction
Pattern family
Resistance11.45
Support9.09
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in PMN

All disclosures →
No recent disclosed trades by Congress in PMN. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in PMN · 10 buys

InsiderSideShares
Mandel-Brehm Josh
Director · Option (right to buy) · 2026-05-20
Grant11K
Kaplan Johanne
Chief Development Officer · Option (right to buy) · 2026-05-20
Grant50K
WYMAN WILLIAM W
Director · Option (right to buy) · 2026-05-20
Grant5.5K
Warma Neil K
Chief Executive Officer · Option (right to buy) · 2026-05-20
Grant160K
Williams Eugene
Director · Option (right to buy) · 2026-05-20
Grant5.5K
Milbury Max A.
Principal Accounting Officer · Option (right to buy) · 2026-05-20
Grant18.17K
Alex Slanix Paul
Director · Option (right to buy) · 2026-05-20
Grant5.5K
Shafmaster Madge K.
Director · Option (right to buy) · 2026-05-20
Grant11K
WYMAN WILLIAM W
Director · Option (right to buy) · 2026-05-20
Grant11K
Williams Eugene
Director · Option (right to buy) · 2026-05-20
Grant11K

SEC filings

EDGAR filings in PMN

EDGAR →

No recent SEC filings on file for PMN.

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.